Preventive effect of ACE inhibitor on interstitial myofibroblast formation and matrix deposition in a nephrotic model

Renal Failure

Volumn 20, Issue 3, 1998, Pages 481-491

  Mizuno, Shinya ^a   Horikawa, Yoko ^a   Okamoto, Munehiro ^a   Kurosawa, Tsutomu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

ACE inhibitor; Mouse model; Myofibroblast; Nephrotic syndrome; Tubulo interstitial fibrosis

Indexed keywords

ALBUMIN; ALPHA ACTIN; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FIBROSIS; MOUSE; MYOFIBROBLAST; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; UREA NITROGEN BLOOD LEVEL;

EID: 0031949391     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229809045137     Document Type: Article

References (30)

1. Risdon RA, Sloper JC, Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363-366, 1968.
2. Bohle A, Strutz F, Muller GA: On the pathogenesis of chronic renal failure in primary glomerulopathies: A view from the interstitium. Exp Nephrol 2:205-210, 1994.
3. Tang WW, Feng L, Mathison JC, Wilson CB: Cytokine expression, upregulation of intercellular adhesion molecule-1, and leukocyte infiltration in experimental tubulointerstitial nephritis. Lab Invest 70:631-638, 1994.
4. Fine LG, Norman JT, Ong A Cell-cell cross-talk in the pathogenesis of renal interstitial fibrosis. Kidney Int 47(suppl 49):548-550, 1995.
5. Ong AC, Fine LG: Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: Implications for human renal disease progression. Am J Kidney Dis 23:205-209, 1994.
6. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 19:464-474, 1992.
7. Arai M, Wada A, Isaka Y, Akagi Y, Sugiura T, Miyazaki M, Moriyama T, Kaneda Y, Naruse K, Naruse M, Orita Y, Ando A, Kamada T, Ueda N, Imai E: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 206:525-532, 1995.
8. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzl P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. J Clin Invest 92:2597-2601, 1993.
9. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666-678, 1996.
10. Hsueh WA, Do YS, Anderson PW, Law RE: Angiotensin II in cell growth and matrix production. Adv Exp Med Bid 377:217-223, 1995.
11. Ruiz OM, Gomez GD, Alcazar R, Palacios I, Bustos C, Gonzalez S, Plaza JJ, Gonzalez E, Egido J: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens 12 (suppl 4):551-558, 1994.
12. Praga M, Hernandez E, Montoyo C, Andres A, Ruiope LM, Rodicio JL: Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20:240-248, 1992.
13. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-254, 1994.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993.
15. Kurosawa T, Okamoto M, Yamada K, Yue B: Nephrosis (nep): A new mouse mutation which causes albuminuria and other symptoms of nephrosis. Mouse Genome 91:876-878, 1993.
16. Tatsumi H, Satoh S, Okamoto M, Nakamura M, Asano T, Kurosawa T: Morphological studies on the kidney of the spontaneous nephrotic (ICON) mice in the late stage. Acta Anat Nippon 70:96-106, 1995.
17. Ogura A, Asano T, Suzuki O, Yamamoto Y, Noguchi Y, Kawaguchi H, Yamaguchi Y: Hereditary nephrotic syndrome with progression to renal failure in a mouse model (ICGN strain): Clinical study. Nephron 68:239-244, 1994.
18. Mizuno S, Yue BF, Okamoto M, Horikawa Y, Kurosawa T: Diffuse glomerulosclerosis without tubular injury does not directly manifest renal dysfunction in nephrotic mice (ICGN strain). Exp Nephrol, in press.
19. Sakemi T, Baba N, Yoshikawa Y: Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats. Nephron 62:315-321, 1992.
20. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:137-143, 1984.
21. Ishidoya S, Morrissey J, McCracken R, Klahr S: Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 49:1110-1119, 1996.
22. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986.
23. Zoja C, Corna D, Bruzzi I, Foglieni C, Bertani T, Remuzzi G, Benigni N Passive heymann nephritis : Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Neohrol 4:213-221, 1996.
24. Ogura A, Fujimura H, Asano T, Koura M, Naito I, Kobayashi Y: Early ultrastructural glomerular alterations in neonatal nephrotic mice (ICGN strain). Vet Pathol 32:321-323, 1995.
25. Nahas AME, Muchaneta-Kubara EC, Zhang G, Adam A, Goumenos D: Phenotypic modulation of renal cells during experimental and clinical renal scarring. Kidney Int 49(Suppl 54):523-527, 1996.
26. Tang WW, Ulich TR, Lacey DL, Hill DC, Qi M, Kaufman SA, Van GY, Tarpley JE, Yee JS: Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 148:1169-1180, 1996.
27. Mizuno S, Horikawa Y, Okamoto M, Kurosawa T: ACE inhibition suppresses tubular expression of PDGF in a nephrotic mouse model. Nephron (letter), in press.
28. Inserra F, Romano LA, Cavanagh EM, Ercole L, Ferder LF, Gomez RA: Renal interstitial sclerosis in aging: Effects of enalapril and nifedipine. J Am Soc Nephrol 7:676-680, 1996.
29. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82:322-330, 1988.
30. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992.